Advisory Committee on Immunization Practices (ACIP); Notice of Meeting and Request for Comment, 45766-45767 [2019-18744]
Download as PDF
<![CDATA[
jspears on DSK3GMQ082PROD with NOTICES
45766
Federal Register / Vol. 84, No. 169 / Friday, August 30, 2019 / Notices
laboratory technologies and
nontraditional testing workflow models,
including next generation sequencing,
biomarker testing, metagenomics, and
others?
3. What data are available that could
assist in answering how CLIA may need
to be revised or where guidance may be
needed to ensure the accuracy and
reliability of emerging technologies?
In general, each individual or group
requesting to make oral comments will
be limited to a total time of ten minutes
(unless otherwise indicated). To assure
adequate time is scheduled for public
comments, speakers should notify the
contact person below at least five
business days prior to the meeting date.
For individuals or groups unable to
attend the meeting or that wish to
provide data in response to the
questions above, CLIAC accepts written
comments until the date of the meeting
(unless otherwise stated). However, it is
requested that comments be submitted
at least five business days prior to the
meeting date so that the comments may
be made available to the Committee for
their consideration and public
distribution. Written comments should
be provided to the contact person at the
mailing or email address below and will
be included in the meeting’s Summary
Report.
The CLIAC meeting materials will be
made available to the Committee and
the public in electronic format (PDF) on
the internet instead of by printed copy.
Check the CLIAC website on the day of
the meeting for materials: www.cdc.gov/
cliac.
Matters To Be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will focus on an update
from the Association of Public Health
Opioids Task Force; an update on the
clinical laboratory workforce; return of
research results to research participants;
and improving integration of laboratory
information systems with electronic
health records. There will be an
extended public comment session
focusing on emerging technologies and
the clinical laboratory. Agenda items are
subject to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
16:43 Aug 29, 2019
Jkt 247001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2019–18745 Filed 8–29–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0073]
Advisory Committee on Immunization
Practices (ACIP); Notice of Meeting
and Request for Comment
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public, limited only by room seating.
The meeting room accommodates 216
for public seating. Room 245, adjacent
to the meeting room, will be available
once the meeting room reaches capacity,
providing up to 18 additional seats.
Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web; for
meeting registration and more
information on ACIP please visit the
ACIP website: https://www.cdc.gov/
vaccines/acip/.
DATES: The meeting will be held on
October 23, 2019 8:00 a.m. to 5:00 p.m.,
EDT, and October 24, 2019 8:00 a.m. to
2:30 p.m. EDT.
Written comments must be received
on or before October 28, 2019.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0073 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS A–27, Atlanta, GA 30329–4027,
Attn: October ACIP Meeting
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
SUMMARY:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov. Written
public comments submitted by 72 hours
prior to the ACIP meeting will be
provided to ACIP members before the
meeting.
Meeting Location: Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Tom Harkin Global
Communications Center, Building 19,
Kent ‘Oz’ Nelson Auditorium, Atlanta,
Georgia, 30329–4027.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE Atlanta, GA 30329–4027; Telephone:
404–639–8367; Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
E:\FR\FM\30AUN1.SGM
30AUN1
jspears on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 84, No. 169 / Friday, August 30, 2019 / Notices
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted in to the
docket.
Oral Public Comment: This meeting
will include time for members of the
public to make an in-person oral
comment. Oral public comment will
occur before any scheduled votes
including all votes relevant to the
ACIP’s Affordable Care Act and
Vaccines for Children Program roles.
Priority will be given to individuals
who submit a request to make an oral
public comment before the meeting
according to the procedures below. Onsite, in-person registration for oral
public comment at the meeting will
only be available if there is time
remaining in the oral public comment
session after all individuals who
submitted a request to make an oral
comment before the meeting have had
an opportunity to speak. There is no
guarantee there will be an opportunity
for on-site, in-person registration for
oral public comment, and all
individuals interested in requesting to
make an oral public comment are
strongly encouraged to submit a request
according to the instructions below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the October ACIP
meeting must submit a request at https://
www.cdc.gov/vaccines/acip/meetings/
no later than 11:59 p.m., EDT, October
9, 2019 according to the instructions
provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for each
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by October 16, 2019. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: Written
comments must be received on or before
October 28, 2019.
Matters to be Considered: The agenda
will include discussions on pertussis
vaccines, child/adolescent
immunization schedule, adult
immunization schedule, influenza
vaccines, general best practices, dengue
vaccine, rabies vaccine, and herpes
zoster vaccine. A recommendation vote
is scheduled for pertussis vaccines,
child/adolescent immunization
VerDate Sep<11>2014
16:43 Aug 29, 2019
Jkt 247001
schedule, and adult immunization
schedule. A Vaccines for Children
recommendation vote is scheduled for
pertussis vaccines. Agenda items are
subject to change as priorities dictate.
For more information on the meeting
agenda visit https://www.cdc.gov/
vaccines/acip/meetings/meetingsinfo.html.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2019–18744 Filed 8–29–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
of the Advisory Board on Radiation and
Worker Health (ABRWH). This meeting
is open to the public, but without a
public comment period. The public is
welcome to submit written comments in
advance of the meeting, to the contact
person below. Written comments
received in advance of the meeting will
be included in the official record of the
meeting. The public is also welcome to
listen to the meeting by joining the
audio conference (information below).
The audio conference line has 150 ports
for callers.
DATES: The meeting will be held on
October 16, 2019, 11:00 a.m. to 1:00
p.m., EDT.
ADDRESSES: Audio Conference Call via
FTS Conferencing. The USA toll-free
dial-in number is 1–866–659–0537; the
pass code is 9933701.
SUMMARY:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
45767
FOR FURTHER INFORMATION CONTACT:
Theodore Katz, MPA, Designated
Federal Officer, NIOSH, CDC, 1600
Clifton Road, Mailstop E–20, Atlanta,
Georgia 30329–4027, Telephone (513)
533–6800, Toll Free 1(800) CDC–INFO,
Email ocas@cdc.gov.
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule, advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule, advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program, and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC). In
December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS,
which subsequently delegated this
authority to the CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
rechartered under Executive Order
13811 on February 12, 2018, and will
terminate on March 22, 2020.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters To Be Considered: The agenda
will include discussions on: Recording
August 2019 Meeting Absentee Votes;
Work Group and Subcommittee Reports;
Update on the Status of SEC Petitions;
Plans for the December 2019 Advisory
Board Meeting; and Advisory Board
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 84, Number 169 (Friday, August 30, 2019)]
[Notices]
[Pages 45766-45767]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18744]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2019-0073]
Advisory Committee on Immunization Practices (ACIP); Notice of
Meeting and Request for Comment
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public, limited only by room
seating. The meeting room accommodates 216 for public seating. Room
245, adjacent to the meeting room, will be available once the meeting
room reaches capacity, providing up to 18 additional seats. Time will
be available for public comment. The meeting will be webcast live via
the World Wide Web; for meeting registration and more information on
ACIP please visit the ACIP website: https://www.cdc.gov/vaccines/acip/.
DATES: The meeting will be held on October 23, 2019 8:00 a.m. to 5:00
p.m., EDT, and October 24, 2019 8:00 a.m. to 2:30 p.m. EDT.
Written comments must be received on or before October 28, 2019.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0073 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS A-27, Atlanta, GA 30329-4027, Attn: October ACIP
Meeting
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted by 72 hours prior to the ACIP meeting
will be provided to ACIP members before the meeting.
Meeting Location: Centers for Disease Control and Prevention, 1600
Clifton Road NE, Tom Harkin Global Communications Center, Building 19,
Kent `Oz' Nelson Auditorium, Atlanta, Georgia, 30329-4027.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE Atlanta, GA 30329-4027; Telephone: 404-639-8367; Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the Director of the Centers for Disease Control and
Prevention and appear on CDC immunization schedules must be covered by
applicable health plans.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or
[[Page 45767]]
proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted in to the docket.
Oral Public Comment: This meeting will include time for members of
the public to make an in-person oral comment. Oral public comment will
occur before any scheduled votes including all votes relevant to the
ACIP's Affordable Care Act and Vaccines for Children Program roles.
Priority will be given to individuals who submit a request to make an
oral public comment before the meeting according to the procedures
below. On-site, in-person registration for oral public comment at the
meeting will only be available if there is time remaining in the oral
public comment session after all individuals who submitted a request to
make an oral comment before the meeting have had an opportunity to
speak. There is no guarantee there will be an opportunity for on-site,
in-person registration for oral public comment, and all individuals
interested in requesting to make an oral public comment are strongly
encouraged to submit a request according to the instructions below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the October ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/acip/meetings/ no later than
11:59 p.m., EDT, October 9, 2019 according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for each scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by October 16, 2019. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: Written comments must be received on or
before October 28, 2019.
Matters to be Considered: The agenda will include discussions on
pertussis vaccines, child/adolescent immunization schedule, adult
immunization schedule, influenza vaccines, general best practices,
dengue vaccine, rabies vaccine, and herpes zoster vaccine. A
recommendation vote is scheduled for pertussis vaccines, child/
adolescent immunization schedule, and adult immunization schedule. A
Vaccines for Children recommendation vote is scheduled for pertussis
vaccines. Agenda items are subject to change as priorities dictate. For
more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-18744 Filed 8-29-19; 8:45 am]
BILLING CODE 4163-18-P
